The study, published in BMC Endocrine Disorders, recruited 102 patients from the endocrinology clinics and wards of Imam Reza and Sina Hospitals in Tabriz. Each participant underwent dual-energy X-ray absorptiometry, the gold-standard imaging technique for measuring bone mineral density, with readings taken at the lumbar spine and the femoral neck, the upper portion of the thigh bone where most hip fractures originate. Following World Health Organization criteria, osteoporosis was defined as a T-score of -2.5 or lower at either site. When degenerative changes in the spine, common in older adults, threatened to distort lumbar measurements, the researchers gave priority to the femoral neck values, a methodological safeguard designed to avoid falsely inflating or deflating the true burden of disease.

The resulting prevalence estimate, 32.4 percent with a 95 percent confidence interval of 23.4 to 42.3 percent, carries a wide margin of uncertainty, reflecting the modest sample size. Even at the lower bound, however, the numbers suggest that nearly a quarter of older diabetic patients in this setting have bones fragile enough to fracture under everyday stresses. That matters because diabetes-related fractures are not ordinary fractures. Studies across multiple populations have shown that people with type 2 diabetes can break hips and vertebrae at bone mineral density levels that would be considered safe in non-diabetic individuals, meaning standard screening thresholds may systematically underestimate their true skeletal risk.

The biological explanation lies partly in a process that has fascinated bone biologists for years: the accumulation of advanced glycation end products, or AGEs. Chronic high blood sugar drives glucose molecules to bind irreversibly to proteins throughout the body, including collagen, the structural scaffold of bone. Glycated collagen becomes stiffer and more brittle, and the normal microscopic repair process, in which bone cells remove and replace damaged tissue, slows down. The result is a bone that may look adequately dense on a scan but behaves mechanically like aged plastic rather than resilient composite material. Diabetes also disrupts the delicate coupling between osteoblasts, the cells that build bone, and osteoclasts, the cells that dismantle it, tilting the balance toward loss.

Against this backdrop, the Tabriz team used logistic regression to identify which characteristics of their patients were actually associated with osteoporosis. Two factors emerged clearly and independently. The first was female sex: women in the cohort had roughly five times the odds of osteoporosis compared with men, an unadjusted odds ratio of 4.84 with a confidence interval of 1.67 to 14.01 and a P value of 0.004. After adjusting for other variables, the association persisted, with an adjusted odds ratio of 3.34 and a P value of 0.035. The finding aligns with decades of bone biology, since the sharp decline in estrogen at menopause removes a powerful protective signal that normally restrains bone resorption, and it suggests that postmenopausal women with diabetes face a compounding of two skeletal threats at once.

The second independent predictor was more surprising to many observers: kidney function. The researchers measured the estimated glomerular filtration rate, or eGFR, a standard laboratory index of how efficiently the kidneys filter blood, expressed in milliliters per minute per 1.73 square meters of body surface area. Lower eGFR was significantly associated with osteoporosis, with an odds ratio of 0.96 per unit increase, a confidence interval of 0.94 to 0.98, and a P value of 0.004. In the multivariable model the relationship held, with an adjusted odds ratio of 0.97 and a P value of 0.037. In practical terms, each incremental decline in filtration capacity nudged patients measurably closer to the osteoporotic range.

The kidney-bone connection is well grounded in physiology. The kidneys are not passive bystanders in skeletal metabolism; they activate vitamin D, regulate calcium and phosphate balance, and orchestrate the hormonal signals that keep bone remodeling on schedule. As filtration declines, phosphate retention and hormonal disturbances trigger a cascade known as chronic kidney disease-mineral and bone disorder, in which parathyroid hormone levels rise and bone turnover becomes disordered. Because diabetic kidney disease is itself one of the most common complications of long-standing type 2 diabetes, the study’s finding effectively identifies a subgroup, older diabetic women with waning renal function, whose bones are being attacked from multiple directions simultaneously.

What the study did not find is equally instructive. Glycemic control, measured through fasting blood sugar and glycated hemoglobin, body mass index, physical activity levels assessed with the International Physical Activity Questionnaire, and medication histories did not emerge as statistically significant independent predictors in this cohort. That may reflect the limited statistical power of a 102-patient sample, or genuine homogeneity among patients recruited from specialized endocrinology services, where most participants receive broadly similar care. The authors are careful on this point, and their conclusion emphasizes that the two robust signals, female sex and reduced eGFR, should guide screening priorities rather than serving as an exhaustive risk map.

The clinical implications are straightforward but consequential. Current guidance in many health systems does not routinely recommend bone density screening for patients with type 2 diabetes until they reach ages well beyond the range of this cohort, partly because diabetes modestly raises body weight, which is traditionally protective against bone loss, and partly because the fracture risk of diabetic patients was underappreciated for years. This study, conducted in a real-world hospital population in northwestern Iran, argues that waiting is a mistake. Integrating a simple DEXA scan and a kidney function check into the routine management of diabetic patients over 55, with heightened vigilance for women, could identify high-risk individuals years before a first fragility fracture, which is often the moment the disease announces itself.

The researchers, led by Yalda Taati Alamdari and corresponding author Mahsa Malekian, with support from the Research Vice-Chancellor of Tabriz University of Medical Sciences, acknowledge the limits of a single-center, cross-sectional design, which captures a snapshot in time and cannot establish whether low kidney function causes bone loss or merely travels alongside it. They call for prospective multicenter studies to sharpen risk stratification and inform screening strategies. With more than half a billion people worldwide now living with diabetes, and populations aging fastest in exactly the regions where diabetes is expanding most rapidly, the study’s central message travels far beyond Tabriz: in older patients with type 2 diabetes, the skeleton is a silent organ of the disease, and the tools to catch its decline already sit in every endocrinology clinic.

Subject of Research: Prevalence and risk factors of osteoporosis among older patients with type 2 diabetes mellitus

Article Title: Prevalence and associated factors of osteoporosis in type 2 diabetes mellitus patients: a cross-sectional study

Article References: Taati Alamdari, Y., Lotfi Yagin, N., Gilani, N., Sadra, V., Najafipour, F., Gaffarzadeh Rad, S., & Malekian, M. (2026). Prevalence and associated factors of osteoporosis in type 2 diabetes mellitus patients: a cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02525-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02525-2

Keywords: type 2 diabetes, osteoporosis, bone mineral density, DEXA, eGFR, kidney function, postmenopausal women, fragility fractures, advanced glycation end products, cross-sectional study, Iran, endocrinology

The study enrolled 1026 children and assessed their diets with a semi-quantitative food-frequency questionnaire, a tool that asks participants how often and in what quantities they consume a defined list of foods over a specified period. From those responses, the researchers estimated intake of individual B vitamins and derived dietary patterns using a statistical technique called reduced-rank regression. Unlike conventional pattern analysis, which simply clusters foods that tend to be eaten together, reduced-rank regression is directional: it searches for the combination of food groups that best explains a predefined intermediate variable, in this case B-vitamin intake. The resulting B-vitamin-rich dietary pattern was characterized by higher consumption of beans, dairy products, meats, grains, eggs, vegetables, and aquatic products, a mix that reads like a reasonably balanced plate rather than an exotic regimen.

To capture the opposite end of the nutritional spectrum, the team constructed a B-Vitamin Deficiency Index, or BVDI, which quantifies cumulative inadequacy across eight B vitamins relative to the Chinese Dietary Reference Intakes. Rather than flagging a single shortfall, the index tallies how many B vitamins a child falls short on, offering a composite picture of nutritional risk. Bone mineral density was measured at the forearm using dual-energy X-ray absorptiometry, the same low-dose imaging technique used to screen adults for osteoporosis. Forearm measurement is a practical choice in pediatric field studies: it is quick, involves minimal radiation, and correlates with skeletal status during growth.

The statistical architecture of the analysis was deliberately cautious. The researchers used multivariable logistic regression to estimate the odds of low bone mineral density across quartiles of intake, adjusting for potential confounders, and they employed restricted cubic splines to model dose-response relationships without forcing them into straight lines. When the results came in, three vitamins stood out. Children in the highest quartile of riboflavin, vitamin B2, had 57 percent lower odds of low bone mineral density than those in the lowest quartile, with an odds ratio of 0.43 and a 95 percent confidence interval of 0.25 to 0.74. Higher intakes of folate, vitamin B9, and cobalamin, vitamin B12, told a similar story, with odds ratios of 0.50 and 0.46 respectively, both statistically significant at conventional thresholds.

The B-vitamin-rich dietary pattern itself showed an inverse but borderline association with low bone mineral density, with an odds ratio of 0.61 and a confidence interval of 0.36 to 1.02 that just grazed the null value of 1.0, yielding a p-value of 0.060. That near-miss is a familiar frustration in nutritional epidemiology, where confidence intervals frequently hover at the edge of significance. It suggests a trend consistent with the individual-vitamin findings but leaves open the possibility that the pattern, as a composite exposure, carries less signal than its components, or that the study size limits the precision of the estimate.

The most striking result concerned the deficiency index. Children in the highest quartile of the BVDI, meaning they had the greatest cumulative inadequacy across the eight B vitamins, had 72 percent higher odds of low bone mineral density than children in the lowest quartile, with an odds ratio of 1.72 and a confidence interval of 1.02 to 2.92. In other words, the more B-vitamin shortfalls a child accumulated, the greater the apparent risk to skeletal density. This graded relationship across the index is notable because it treats B-vitamin status as a spectrum rather than a binary deficiency, reflecting the reality that marginal inadequacy, not just frank deficiency, may matter during the years when the skeleton is being built.

Why would B vitamins influence bone at all? The biological plausibility rests on several mechanisms, some of which are supported by experimental work cited in the study. Riboflavin functions as a cofactor in energy metabolism and has antioxidant properties; animal research has shown that riboflavin deficiency reduces bone mineral density by compromising osteoblast function, the activity of the cells that build bone matrix. Folate and vitamin B12 participate in one-carbon metabolism, the biochemical pathway that keeps levels of homocysteine, an amino acid, in check. Elevated homocysteine has been identified as a pathological biomarker for bone disease, implicated in disrupting collagen cross-linking and stimulating bone resorption. Genetic evidence adds another layer: a well-known study found that a polymorphism in the methylenetetrahydrofolate reductase gene interacts with riboflavin intake to influence bone mineral density, hinting that B-vitamin status can modulate genetically determined skeletal risk.

The pediatric context amplifies the stakes. Peak bone mass, the maximum bone strength a person achieves, is largely laid down during childhood and adolescence, and deficits during this window can persist for decades, raising lifetime fracture and osteoporosis risk. Most research on B vitamins and bone has focused on older adults, where trials have examined supplementation effects on density and fracture. Evidence in children has been thinner, which is what makes this study’s population approach noteworthy. It also aligns with related work: meta-analyses of randomized trials have found that dairy supplementation improves bone health indices in children aged three to eighteen, and a two-year randomized trial in adults with lower vitamin B12 status showed that low-dose B-vitamin supplementation benefited bone mineral density, suggesting the mechanism is not confined to any one life stage.

The authors are careful about what their design can and cannot show. As a cross-sectional study, it captures diet and bone density at a single point in time, so it cannot establish that B-vitamin intake causes stronger bones. Children who eat more B-vitamin-rich foods may differ in many ways from those who do not, including in overall diet quality, physical activity, socioeconomic circumstances, and body composition, and although the analysis adjusted for measured confounders, residual confounding remains possible in any observational study. Reverse causation is less of a concern for dietary exposures than for, say, physical activity, but the temporal ordering of diet and bone status is still unresolved. The findings are best read as a hypothesis-generating signal that B-vitamin nutritional status may be related to skeletal health indicators in childhood, a framing the authors adopt explicitly.

Even with those caveats, the study adds a practical dimension to pediatric nutrition. The foods that defined the B-vitamin-rich pattern, including beans, dairy, meats, grains, eggs, vegetables, and aquatic products, are ordinary components of a varied diet, and the analysis suggests that the collective contribution of these foods to B-vitamin status may matter for growing skeletons. If future longitudinal studies and randomized trials confirm the association, B vitamins could join the roster of nutrients that pediatricians and parents consider when planning diets for school-aged children, alongside calcium and vitamin D. For now, the message is measured: three specific B vitamins and a composite deficiency index are associated with bone mineral density in Chinese children aged nine to twelve, and the cumulative burden of inadequacy appears to matter more than any single shortfall. In the architecture of the growing skeleton, it seems, the supporting cast of nutrients may deserve more attention than it has traditionally received.

Subject of Research: Associations between B-vitamin intake, B-vitamin-rich dietary patterns, and bone mineral density in school-aged children

Article Title: The role of B-vitamin intake, B-vitamin-rich dietary patterns, the B-vitamin deficiency index in bone mineral density among school-aged children

Article References: Tan, L., Zhang, Y., Cui, N., Huang, S., Weng, S., Bao, M., Jiang, Y., Huang, M., & Yang, X. (2026). The role of B-vitamin intake, B-vitamin-rich dietary patterns, the B-vitamin deficiency index in bone mineral density among school-aged children. Pediatric Research. https://doi.org/10.1038/s41390-026-05403-8

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05403-8

Keywords: B vitamins, bone mineral density, children, riboflavin, folate, vitamin B12, dietary patterns, B-Vitamin Deficiency Index, pediatric nutrition, dual-energy X-ray absorptiometry, homocysteine, osteoporosis

The hemoglobin glycation index, usually abbreviated HGI, is calculated by comparing the HbA1c value actually measured in a patient’s blood with the HbA1c value that would be predicted from that patient’s fasting plasma glucose. HbA1c reflects the percentage of hemoglobin molecules that have been chemically modified by glucose over the roughly two-to-three-month lifespan of red blood cells. Because individuals differ in how readily glucose binds to their hemoglobin, two patients with identical average glucose can show different HbA1c readings. The index captures this individual discrepancy: a positive value means the measured HbA1c runs higher than expected for the observed glucose, a phenomenon sometimes described as high glycators, while a negative value indicates the opposite tendency.

To investigate whether this glycation fingerprint matters for bone, the researchers retrospectively analyzed 757 hospitalized patients with type 2 diabetes who had undergone dual-energy X-ray absorptiometry, the standard technique for measuring bone mineral density, between January and December 2023. Dual-energy X-ray absorptiometry works by scanning the skeleton with X-ray beams at two different energy levels and calculating how much of each beam is absorbed by bone tissue, yielding a precise estimate of mineral content. Lumbar osteoporosis was defined using the T-score, which compares a patient’s bone density at the first through fourth lumbar vertebrae with the average density of a healthy young adult. A T-score of negative 2.5 or lower meets the conventional threshold for osteoporosis.

The results were unambiguous in direction. Overall, 208 of the 757 participants, or 27.5 percent, had lumbar osteoporosis. When the researchers divided the cohort into tertiles, three groups of equal size ranked by HGI, the prevalence of lumbar osteoporosis climbed steadily across the groups, from 15.8 percent in the lowest tertile to 28.6 percent in the middle tertile and 38.1 percent in the highest. In other words, patients whose hemoglobin showed the greatest degree of glycation relative to their measured glucose levels were more than twice as likely to have osteoporotic lumbar spines as those in the lowest group.

Because simple prevalence comparisons can be distorted by age, sex, body weight, kidney function and other confounders, the team turned to logistic regression, a statistical technique that models the probability of a binary outcome, here the presence or absence of osteoporosis, as a function of multiple explanatory variables. In the fully adjusted primary model, which included 687 participants with complete data, each one-unit increase in HGI was associated with 34 percent higher odds of lumbar osteoporosis, with an odds ratio of 1.342 and a 95 percent confidence interval running from 1.168 to 1.546, a result that was highly statistically significant. The confidence interval indicates that, given the data, the true effect very likely lies well above the null value of 1.0, meaning no association.

A critical question for any study involving HbA1c is whether the index is merely re-describing what HbA1c or fasting glucose already reveal. To address this, the researchers performed sensitivity analyses in which they additionally adjusted for HbA1c itself and, separately, for fasting plasma glucose. The association survived both tests. With additional adjustment for HbA1c, the odds ratio was 1.251, with a confidence interval of 1.039 to 1.507 and a P value of 0.018. With additional adjustment for fasting glucose, the odds ratio was 1.337, with a confidence interval of 1.164 to 1.540 and a P value below 0.001. This pattern suggests that HGI carries information about bone health that is not redundant with either component used to compute it.

The team also examined bone density as a continuous outcome rather than a binary diagnosis. Higher HGI was associated with a lower T-score across the first through fourth lumbar vertebrae, with a standardized coefficient of negative 0.134 and a confidence interval of negative 0.236 to negative 0.031, statistically significant at P equal to 0.011. Restricted cubic spline models, which allow the relationship between exposure and outcome to bend flexibly rather than being forced into a straight line, were used to probe for nonlinearity in the association. Together, these secondary analyses reinforced the primary finding that the glycation index tracks with progressively weaker lumbar bone density.

Perhaps the most intriguing results came from the exploratory analysis of bone turnover markers, molecules released into the bloodstream during the constant remodeling of skeletal tissue. Osteocalcin, a protein secreted by osteoblasts, the cells that build new bone, serves as a marker of bone formation. PINP, a fragment of type I collagen propeptide, marks the synthesis of new bone matrix, while beta-CTX, a collagen degradation product, reflects bone resorption by osteoclasts. In this cohort, higher HGI was inversely associated with osteocalcin, with a coefficient of negative 0.057 and a confidence interval of negative 0.103 to negative 0.011, statistically significant at P equal to 0.016. Associations with PINP and beta-CTX did not reach statistical significance. The authors are careful to characterize the osteocalcin finding as modest and exploratory, but it hints at a possible mechanism: chronic non-enzymatic glycation of bone matrix proteins, including osteocalcin itself, may impair bone quality even when the quantity of mineral looks adequate on a scan.

This mechanistic hypothesis fits a broader picture that bone scientists have been assembling for years. In diabetes, skeletal fragility is thought to arise less from low bone mass and more from degraded bone material properties. Glucose can attach to collagen and other matrix proteins without the help of enzymes, forming advanced glycation end-products that stiffen collagen fibers and make bone more brittle under stress, even though the tissue appears denser on absorptiometry. A hemoglobin glycation index that runs high may flag patients whose tissues are more exposed to this process, offering a window into bone quality that bone mineral density measurements alone cannot provide. The inverse link with osteocalcin, a formation marker, could indicate suppressed or altered bone-building activity in high-glycating patients, though the cross-sectional data cannot establish which comes first.

The researchers are equally clear about the limits of their work. Because the study is cross-sectional, capturing a single moment in time, it demonstrates association rather than causation; it cannot show whether a high glycation index precedes bone loss or merely accompanies it. The cohort consisted of hospitalized patients, a group that may differ systematically from the broader population of people with type 2 diabetes, and the authors note the absence of formal discrimination or reclassification analyses, meaning the study did not test whether adding HGI to existing models actually improves the prediction of osteoporosis beyond HbA1c. Still, the findings open a compelling line of inquiry for a disease in which fractures carry enormous costs in mobility, independence and mortality. If future longitudinal studies confirm that the hemoglobin glycation index identifies patients at skeletal risk that standard glucose metrics miss, this inexpensive calculation, derivable from two routine blood tests, could become a practical tool for flagging which of the hundreds of millions of people worldwide living with type 2 diabetes need their bones watched as closely as their blood sugar.

Subject of Research: Association between the hemoglobin glycation index and lumbar osteoporosis in patients with type 2 diabetes

Article Title: Association between hemoglobin glycation index and lumbar osteoporosis in patients with type 2 diabetes mellitus: a cross-sectional study with exploratory analysis of bone turnover markers

Article References: Chen, C., Yang, J., Jiang, X., Wang, Q., Wang, X., & Zhang, X. (2026). Association between hemoglobin glycation index and lumbar osteoporosis in patients with type 2 diabetes mellitus: a cross-sectional study with exploratory analysis of bone turnover markers. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02615-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02615-1

Keywords: hemoglobin glycation index, type 2 diabetes, osteoporosis, bone mineral density, HbA1c, lumbar spine T-score, bone turnover markers, osteocalcin, dual-energy X-ray absorptiometry, advanced glycation end-products, endocrinology, metabolic bone disease

The research was motivated by a biological hypothesis that has been gaining traction over the past two decades: the existence of a bone-pancreas-testis axis. Osteocalcin, secreted by osteoblasts during bone remodeling, is not merely a marker of skeletal turnover. Animal studies have shown that the undercarboxylated, hormonally active form of osteocalcin stimulates insulin secretion by pancreatic beta cells and enhances insulin sensitivity in peripheral tissues. In parallel, osteocalcin appears to influence testosterone biosynthesis, acting on Leydig cells in the testes to promote production of the male sex hormone. Testosterone, in turn, supports bone mass in men by regulating osteoblast and osteoclast activity. If this feedback loop operates in humans as it does in mice, then a metabolic disturbance such as prediabetes could, in principle, ripple through the entire axis — altering insulin, sex hormones, and bone quality simultaneously.

To test that idea, the team recruited 65 men with prediabetes and compared them with 66 healthy controls who were carefully matched for age and body mass index, two variables that independently influence both glucose metabolism and skeletal health. Matching for BMI was a critical design choice, because adiposity confounds nearly every hormone measured in the study: fat tissue aromatizes testosterone into estrogen, drives chronic low-grade inflammation, and mechanically loads the skeleton in ways that stimulate bone formation. By holding age and BMI constant across groups, the investigators could more cleanly isolate the effects of dysglycemia itself. Blood samples were drawn to quantify serum insulin, osteocalcin, interleukin 6, C-reactive protein, follicle-stimulating hormone, luteinizing hormone, total testosterone, and dehydroepiandrosterone sulfate, a weaker adrenal androgen that serves as a precursor for sex steroid synthesis.

Bone status was assessed with dual-energy X-ray absorptiometry, the workhorse technology of clinical osteoporosis evaluation, at four sites: the lumbar vertebrae, the neck of the left femur, the total hip, and — less conventionally — the lumbar spine trabecular bone score, abbreviated LS TBS. The trabecular bone score is a textural analysis of standard DXA images that estimates the microarchitectural integrity of cancellous bone, the spongy, honeycombed tissue that fills the interior of vertebrae and bears much of the spine’s load. Unlike areal bone mineral density, which measures how much mineral is packed into a scanned area, TBS captures how that mineral is organized. Two spines with identical density can differ sharply in trabecular connectivity, and the one with degraded microarchitecture fractures more easily. This distinction proved to be the crux of the new findings.

The hormonal results were unambiguous. Prediabetic men had significantly lower total testosterone than their normoglycemic counterparts, a difference that reached statistical significance at p equals 0.030, and markedly lower osteocalcin, at p equals 0.004. The osteocalcin finding is particularly intriguing given the hormone’s proposed role in glucose regulation: reduced osteocalcin in a prediabetic population fits the circular logic of the bone-pancreas axis, in which impaired insulin signaling suppresses osteoblast activity, lowering osteocalcin output, which in turn may further weaken insulin secretion and sensitivity. The researchers also measured two inflammatory markers, interleukin 6 and C-reactive protein, because chronic inflammation is a recognized suppressor of osteoblast function and a plausible mechanistic bridge between metabolic dysfunction and skeletal deterioration.

Yet when the investigators examined the relationships among these hormones, the expected connections did not all materialize. Total testosterone showed no significant association with fasting insulin levels or with the homeostasis model assessment-estimated insulin resistance index, the widely used HOMA-IR calculation derived from fasting glucose and insulin. However, testosterone was inversely related to the metabolic score for insulin resistance, or METS-IR, a newer surrogate index that incorporates body mass index, fasting glucose, and triglycerides rather than insulin measurements. The divergence between the two indices is itself informative: METS-IR was designed to capture insulin resistance in settings where insulin assays are unavailable, and it weights adiposity and lipid metabolism more heavily. An inverse testosterone-METS-IR relationship in prediabetic men suggests that the hormone tracks with broader metabolic dysfunction rather than with insulin concentration per se, though the cross-sectional design of the study cannot establish which direction any causality might run.

The skeletal findings told a story of apparent paradox. At the conventional DXA sites — lumbar spine, femoral neck, and total hip — bone mineral density was statistically similar between the prediabetic and control groups. On the surface, this suggests that prediabetes spares the skeleton. But the trabecular bone score told a different tale: prediabetic men had significantly lower LS TBS than their normoglycemic peers, indicating degraded trabecular microarchitecture despite preserved density. Moreover, within the prediabetic group, interleukin 6 levels correlated negatively with LS TBS, meaning that men with higher circulating concentrations of this pro-inflammatory cytokine tended to have worse trabecular texture scores. This aligns with a growing body of evidence that inflammation erodes bone quality through mechanisms that density measurements do not capture, including increased osteoclast activation and disruption of the coupling between bone resorption and formation.

One further result underscored the dominant role of body composition in male skeletal health: within the prediabetic group, BMI was significantly associated with bone density. Heavier men carried denser bones, a mechanical effect of load-bearing that is among the most robust findings in osteology. But BMI’s protective association with density may coexist with harm to quality, since visceral adiposity fuels the inflammatory milieu implicated in the TBS reductions. The study’s authors are appropriately cautious in interpreting these patterns. They conclude that despite lower testosterone and osteocalcin, bone density in prediabetic men resembles that of controls, yet trabecular bone score is reduced — and they explicitly state that the potential influence of sex hormones and metabolic abnormalities on bone density or quality in this population remains uncertain and warrants further research.

The clinical implications, if confirmed, could be consequential. Prediabetes affects an estimated hundreds of millions of adults worldwide, and men with the condition may currently be reassured by normal DXA density readings that overlook microarchitectural decline. TBS is already integrated into fracture-risk assessment tools in many clinics, and the new findings suggest it may add value specifically in metabolically compromised patients whose density scans appear reassuring. Longitudinal studies will be needed to determine whether prediabetic men with low TBS actually sustain more fragility fractures, and whether interventions that improve insulin sensitivity — exercise, weight management, or pharmacotherapy — simultaneously restore osteocalcin, testosterone, and trabecular integrity. For now, the study adds a compelling piece to the puzzle of how metabolism and skeleton converse, and a reminder that the most important changes in bone health may be the ones standard scans cannot see.

Subject of Research: The relationship between sex hormones, osteocalcin, and bone parameters in men with prediabetes

Article Title: Sex hormones and osteocalcin levels in relation to bone parameters: a study on male subjects with prediabetes

Article References: Karimi, F., Jeddi, M., & Behdadnia, A. (2026). Sex hormones and osteocalcin levels in relation to bone parameters: a study on male subjects with prediabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02598-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02598-z

Keywords: prediabetes, osteocalcin, testosterone, bone density, trabecular bone score, insulin resistance, METS-IR, interleukin-6, bone-pancreas-testis axis, dual-energy X-ray absorptiometry, endocrinology, men's health

The concern is rooted in the pharmacology of the drug class itself. SGLT2 inhibitors lower blood glucose by blocking glucose reabsorption in the kidney, flushing roughly 60 to 80 grams of glucose into the urine each day. That caloric loss drives weight reduction, which is often marketed as a benefit, particularly for patients with obesity. But evidence drawn mainly from trials in heavier patients suggests the lost weight may include not only fat but also skeletal muscle, raising the specter of sarcopenia, the age-related loss of muscle mass and strength that predisposes older adults to frailty, falls, disability, and death. In a country where most people with type 2 diabetes do not meet the Japanese threshold for obesity, the question is not academic.

Previous data have been ambiguous. The EMPA-ELDERLY trial, which tested empagliflozin in Japanese adults aged 65 and older, found that the drug improved glycemic control and promoted weight loss without compromising muscle mass or strength. Yet that trial enrolled participants with a mean body mass index of 25.6 kilograms per square meter, a figure that qualifies as obese under Japanese criteria. In other words, even the most reassuring study to date was conducted in a population that does not resemble the lean, older Japanese patient most likely to receive these drugs in everyday practice. The TIGHTEN investigators argue that this gap leaves clinicians prescribing in a zone of genuine uncertainty.

The trial itself is deliberately straightforward. It is a prospective, multicenter, open-label, randomized, parallel-group comparative study conducted at three sites in Ishikawa Prefecture: Kanazawa Medical University Hospital, Asanogawa General Hospital, and Kanazawa Nakade Clinic. Participants are adults with type 2 diabetes whose body mass index is below 25 kilograms per square meter, the Japanese cutoff for obesity, and whose glycated hemoglobin sits between 7.0 and just under 10.0 percent. Patients with an estimated glomerular filtration rate below 30 milliliters per minute per 1.73 square meters are excluded, consistent with the safety labeling of both drugs. After informed consent, participants are centrally randomized in a one-to-one ratio using the minimization method, balanced for sex and for age below or above 70 years.

One arm receives 20 milligrams of tofogliflozin orally once daily for 24 weeks. The other starts glimepiride at 0.5 to 1 milligram per day, with dose adjustments between 0.5 and 4 milligrams permitted at the treating physician’s discretion to reach glycemic targets while avoiding hypoglycemia. All participants follow a diet calibrated to their target body weight and maintain daily physical activity in line with Japan Diabetes Society guidelines. Changes to other antidiabetic medications are not permitted in principle during the study, ensuring that any differences in body composition can be attributed to the assigned treatment rather than to shifting polypharmacy.

The primary endpoint is the change in the ratio of total skeletal muscle mass to total body weight from baseline to 24 weeks. That choice is more subtle than it looks. Because body weight is the denominator, the ratio can rise simply because weight falls, even if absolute muscle mass declines. The investigators have anticipated this trap and pre-registered a battery of secondary measures to guard against a misleading result: percentage change in the muscle-to-weight ratio, the skeletal muscle mass index calculated by dividing appendicular lean mass by height squared, absolute total lean body mass, appendicular lean mass, total and relative fat mass, and dietary intake measured with the Brief-type Self-administered Diet History Questionnaire. If the ratio climbs while absolute lean mass or the muscle index falls, the increase will be interpreted as denominator-driven rather than as evidence of muscle preservation.

All body composition measurements will be performed with a single dual-energy X-ray absorptiometry system at Kanazawa Medical University Hospital, a design decision meant to eliminate the inter-scanner variability that can plague multicenter imaging studies. Blood counts, glycemic parameters, a full biochemical panel, urinary albumin excretion, blood pressure, and body weight round out the observation schedule. An independent data center and data and safety monitoring board manage the trial’s data and monitor its conduct, and adverse events, including exacerbations of preexisting conditions, are systematically captured and reported.

The sample size is modest but justified. Drawing on a prior trial of dapagliflozin versus glibenclamide that reported changes in the muscle-to-weight ratio of 0.012 versus 0.001, the investigators assumed a between-group difference of 0.011 with a standard deviation of 0.011. With a two-sided alpha of 0.05 and 90 percent power, 23 participants per group suffice; adding a 15 percent dropout allowance brings the target to 56 participants. Recruitment ran from April 2024 to June 2025, and complete findings are expected in 2027. No interim analysis is planned; the primary endpoint will be analyzed with analysis of covariance adjusting for treatment group, sex, age category, and the baseline muscle-to-weight ratio, with per-protocol analyses as sensitivity checks.

The open-label design, the restriction to Japanese patients, and the 24-week horizon all limit how far the results can travel, and the authors acknowledge each of these constraints. Still, the trial will be the first randomized study to test the effects of an SGLT2 inhibitor on DXA-measured skeletal muscle mass in patients with type 2 diabetes who are not obese, and it sets no lower limit on body mass index, meaning it will capture even very lean participants with BMI values below 20. For millions of older, lean patients with type 2 diabetes worldwide, and for the physicians weighing cardiorenal protection against the hidden cost of frailty, the answer cannot come soon enough.

Subject of Research: Effects of the SGLT2 inhibitor tofogliflozin versus glimepiride on skeletal muscle mass in patients with type 2 diabetes without obesity

Article Title: Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan

Article References: Takeda, Y., Ozawa, T., Ikoma, M., Shimada, K., Saito, R., Nakagawa, A., Sawamura, T., & Kumashiro, N. (2026). Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01920-1

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01920-1

Keywords: SGLT2 inhibitor, tofogliflozin, glimepiride, type 2 diabetes, sarcopenia, skeletal muscle mass, randomized trial, dual-energy X-ray absorptiometry, Japan, Diabetes Therapy, clinical trial protocol, body composition

The research team, led by Bing-Hao Lu, Wei-Han Lin, and Kuo-Yuan Huang, focused on a group of patients who are, in many respects, the clinical frontline of the osteoporosis epidemic: 230 hospitalized adults who had undergone surgery for fragility fractures of the hip or spine. These are the fractures that occur when a fall from standing height, or even a trivial mechanical insult, is enough to break bone weakened by age-related mineral loss. Hip fractures in particular carry a grim prognosis, with prior meta-analyses showing excess mortality that persists for years after the injury, alongside substantial long-term disability. Identifying better tools to stratify skeletal risk in such patients is therefore not an academic exercise but a pressing clinical need, because the first fragility fracture is one of the strongest predictors that a second one will follow.

Abdominal aortic calcification offers an attractive candidate marker because it can be observed on imaging that many of these patients already undergo. The researchers quantified AAC on lateral spine radiographs using the 24-point Kauppila score, a well-established semiquantitative index that grades the severity of calcified deposits along both the anterior and posterior walls of the aorta across four lumbar vertebral segments. By summing the scores at each level, the method yields a continuous measure of calcification burden ranging from zero to 24. The technique has a long pedigree: it was first developed in the Framingham Heart Study population, where aortic calcific deposits were shown to predict vascular morbidity and mortality, and it has since been adapted for use with dual-energy X-ray absorptiometry images, potentially allowing osteoporosis screening visits to double as vascular assessments.

The biological rationale for a bone-vascular link is compelling. Both bone mineralization and vascular calcification involve the deposition of calcium phosphate crystals, but they sit at opposite ends of a regulatory spectrum. Cells in the vascular wall, under conditions of oxidative stress, inflammation, disordered mineral metabolism, and aging, can adopt an osteoblast-like phenotype and actively lay down bone-like matrix within the artery. Meanwhile, the same molecular pathways, including osteoprotegerin, bone morphogenetic proteins, and vitamin K–dependent proteins such as matrix Gla protein, participate in regulating both processes. Epidemiological evidence has repeatedly connected the two: lower bone mineral density has been associated with coronary artery calcium, and aortic calcification has been linked to bone loss over 25-year follow-up in the Framingham cohort. Systematic reviews and meta-analyses of observational studies have reported that higher AAC burden is associated with lower bone mineral density and increased fracture risk in general populations.

Against this backdrop, the Taiwanese team set out to test whether AAC could meaningfully stratify skeletal outcomes in patients who had already fractured. They examined associations between AAC burden and bone mineral density measured by dual-energy X-ray absorptiometry, with particular attention to the femoral neck, the site most relevant to hip fracture. They also explored relationships with FRAX-estimated fracture probabilities, the widely used algorithm that integrates clinical risk factors with or without bone density to estimate ten-year fracture likelihood. Fracture severity was graded using established classification systems, including the semiquantitative method for vertebral fractures and the Garden and Evans classifications for femoral neck and trochanteric hip fractures, respectively. Finally, the investigators tracked refracture over time using Kaplan-Meier survival curves and Cox proportional hazards models, anchoring all follow-up to a common baseline defined as the latest of three dates: the index operation, the bone density scan, and the radiographic AAC assessment.

The headline result was a genuine but fragile association. In unadjusted analyses, higher AAC scores were significantly correlated with lower femoral neck bone mineral density, with a Spearman correlation coefficient of −0.230 and a p-value below 0.001. This is consistent with the broader literature and suggests that, at the crude level, calcified arteries and demineralized femoral necks do travel together in fracture patients, just as they do in community cohorts. However, when the researchers adjusted for potential confounders in multivariable regression models, the association was attenuated and lost its independent statistical footing. In other words, much of the apparent relationship between aortic calcification and low bone density in these patients could be explained by factors that AAC and bone density share in common: advancing age, sex, and body-composition characteristics.

The same pattern of attenuated significance held for the other skeletal outcomes. Although AAC showed weak positive correlations with FRAX-estimated probabilities of major osteoporotic and hip fracture, it did not independently predict the severity of the vertebral or hip fractures that brought these patients to the operating room in the first place. A more severe calcification burden did not translate into a more comminuted fracture, a higher-grade compression deformity, or a worse anatomic pattern. This finding cuts against the intuitive expectation that vascular disease and skeletal fragility would progress in lockstep, even within a population already selected for having sustained a fragility fracture.

Perhaps the most clinically consequential result concerned refracture risk. Among the 224 patients who could be followed from the common baseline, 24 experienced a first refracture during the observation period. Refracture-free survival, plotted by Kaplan-Meier analysis, did not differ between patients with higher and lower AAC burdens, and the log-rank test yielded a p-value of 0.982, indicating near-identical curves. In the multivariable Cox model, high AAC was not associated with refracture risk, with a hazard ratio of 0.90 and a 95 percent confidence interval of 0.38 to 2.15, spanning unity comfortably. The authors are appropriately cautious here, noting that the refracture analysis should be interpreted as exploratory because the number of events was limited, which widens confidence intervals and reduces the study’s power to detect modest effects. Still, the direction of the result offers no encouragement that AAC adds predictive value in this setting.

The broader significance of the study lies in what it says about context dependence in biomarker research. Most of the evidence linking AAC to skeletal outcomes comes from community-dwelling populations undergoing routine osteoporosis screening, where recent work, including automated AAC quantification combined with trabecular bone score, has suggested independent fracture prediction. But patients who have already fractured and require hospitalization and surgical fixation represent a different clinical universe: they are older, frailer, and closer to the severe end of the bone-vascular disease spectrum. Within such a selected cohort, the variance in skeletal health attributable to vascular calcification may already be absorbed by the very fact of the fracture, and by the demographic and body-composition factors that drove both processes. The authors conclude that AAC showed limited independent value for skeletal stratification in this inpatient cohort beyond shared demographic and body-composition factors. For clinicians, the message is that a calcified aorta glimpsed on a lateral spine film should not be treated as a surrogate for a fragile skeleton or a forthcoming refracture in fracture patients, even as it retains well-documented value as a marker of cardiovascular risk. For researchers, the study is a reminder that biomarkers validated in screening populations must earn their place, study by study, in the more complex terrain of acute fracture care.

One practical implication concerns how AAC is measured in routine care. Because the Kauppila scoring system can be applied to lateral spine images acquired during standard densitometry, vascular calcification assessment requires no additional radiation exposure or cost, which explains much of the enthusiasm for integrating it into fracture risk workflows. The present findings temper that enthusiasm for inpatient populations, but they do not negate the score’s established role in cardiovascular prognostication, where meta-analytic evidence links aortic calcification to incident vascular events and mortality.

Several design features of the study merit consideration when weighing its conclusions. The retrospective single-center design means that AAC burden was quantified from radiographs obtained for clinical rather than research purposes, and the timing of imaging relative to the index fracture may have varied across patients. The modest sample size of 230, while respectable for an inpatient fracture cohort, limits the precision of adjusted estimates, and the 24 refracture events provide only coarse resolution for survival modeling. Selection factors inherent to hospitalization, including the decision to obtain lateral spine imaging and DXA, may also have shaped the cohort in ways that are difficult to quantify. Future prospective studies with standardized imaging protocols, larger event counts, and longer follow-up will be needed to determine whether AAC retains any incremental prognostic value once fracture has occurred, or whether its utility remains confined to community screening settings.

Subject of Research: The association between abdominal aortic calcification and bone mineral density, fracture severity, and refracture risk in hospitalized patients with surgically treated fragility fractures.

Article Title: Abdominal aortic calcification and skeletal outcomes in hospitalized patients with surgically treated fragility fractures: a retrospective cohort study

Article References: Lu, B.-H., Lin, W.-H., & Huang, K.-Y. (2026). Abdominal aortic calcification and skeletal outcomes in hospitalized patients with surgically treated fragility fractures: a retrospective cohort study. Archives of Osteoporosis, 21(1), Article 137. https://doi.org/10.1007/s11657-026-01755-0

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01755-0

Keywords: abdominal aortic calcification, bone mineral density, fragility fracture, refracture, osteoporosis, FRAX, Kauppila score, hip fracture, vertebral fracture, vascular calcification, dual-energy X-ray absorptiometry, retrospective cohort study